Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies.
about
Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortalityCholesterol-lowering drugs and incident open-angle glaucoma: a population-based cohort studyThe EKZ/AMC childhood cancer survivor cohort: methodology, clinical characteristics, and data availability.Methods of data collection and definitions of cardiac outcomes in the Rotterdam StudyThe Rotterdam Study: 2012 objectives and design update.Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study.Selective serotonin re-uptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment.The impact of time-window bias on the assessment of the long-term effect of medication adherence: the case of secondary prevention after myocardial infarctionThe Rotterdam Study: 2016 objectives and design update.Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers.The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis.Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan.Death and cardiovascular events after bacteriuria among adult women with chronic kidney disease.Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome.Labor epidural anesthesia, obstetric factors and breastfeeding cessation.Clopidogrel use is associated with an increased prevalence of cerebral microbleeds in a stroke-free population: the Rotterdam study.Proton pump inhibitors and gastroenteritis.Sitagliptin and heart failure hospitalization in patients with type 2 diabetesNon-steroidal anti-inflammatory drugs and the risk of atrial fibrillation: a population-based follow-up study.A review on thiazolidinediones and bladder cancer in human studies.Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer.Medication-related fall incidents in an older, ambulant population: the B-PROOF study.CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance.Beta-blocker use and fall risk in older individuals: Original results from two studies with meta-analysis.The importance of considering competing treatment affecting prognosis in the evaluation of therapy in trials: the example of renal transplantation in hemodialysis trials.Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome.Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study.How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women?Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.Determinants and Predictors of Grief Severity and Persistence: The Rotterdam Study.Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A retrospective cohort analysis of the National Health Insurance database in Taiwan.Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus.ABCB1 gene variants, digoxin and risk of sudden cardiac death in a general population.Drug exposure in register-based research-An expert-opinion based evaluation of methods.Digoxin and mortality: lessons for observational studies.Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.The Rotterdam Study: 2014 objectives and design update.Incident cancer risk after the start of aspirin use: results from a Dutch population-based cohort study of low dose aspirin users.
P2860
Q28487938-87B3FE04-7113-42E1-B2F3-62F936C9CED1Q28740349-233561C5-2E2D-4854-8F52-A66DAB02AC72Q30620316-33C14A68-30A0-4EBC-99B1-78F8FAAEE6D8Q34184048-532C2E57-CB78-4E5D-8214-394AC2A1815CQ35201574-6798C20E-A281-44A2-9EBD-4554CCD8331FQ35587424-496B210F-D03B-4920-B71D-4A6F211E8600Q35620231-6DF3B6A3-E169-43B4-B905-0001236766D0Q35624607-53EF3AA6-8BC8-4A46-92BF-5B2579B58548Q35739935-A3E66B59-2DA9-4FF4-8C0D-F35BAD171DD1Q36084114-13163752-8D0A-40EC-BE49-DFFDCEB6C7C3Q36088018-DD2C2B94-15AC-4A90-9F0A-2DE461F73D6AQ36261529-65F5FA64-ECD6-4658-86DE-1788BF9DDC0FQ36281192-515A76CA-E5BE-4044-AAF9-BB2B09C67C65Q36429599-42539A42-C514-4000-AAE7-6E4A5F2B1BEAQ36493369-AA0DEF6F-4FCC-46F9-BC51-7BF23913E011Q36754226-3BACC14C-008C-4D46-9BF0-8EADFFB64D2AQ37328795-7F388F4B-57C9-4A70-9B89-9D365C7A2475Q37341862-1CE08DEF-05A7-4640-9EC9-76D600912990Q37641835-6368E38A-572C-416F-901F-8115B050B7E8Q37704435-6FD096F0-CC74-4952-B7B8-68A93A72F741Q38193601-085548EE-9474-4674-AFBF-33D299087A5AQ38364806-81D38563-485A-49D6-9461-15536E206D5AQ38417824-4F06274B-F40D-4CF3-84E9-76CDEDA7D1ABQ38442184-57A0F1C0-014F-4B79-9AEA-58E2CA6316CBQ38701074-B51AA198-4F38-4340-986E-A45B84475641Q38739070-AB1B4451-74BF-456B-ABF2-8DE1AEA7CE6BQ38878802-B8F925EA-79B9-434A-8D1E-2C2FF017BE54Q38998154-DA396757-4495-4536-BC9B-983F1A78D0BBQ39029165-4CECC838-D900-4202-A2DA-4D4570E727ACQ39886560-71084FA0-4E18-4E00-BE97-06B119AC3621Q40060735-05FDCC50-462C-4763-97C3-C1AC282D6C80Q40118074-5D77909B-D644-4B6C-B86D-DBDEFE8FE0CDQ40478079-48098EB2-BCD8-4AD0-9630-8FF5C2865E5EQ41143859-68165AD6-67A7-42BB-B35F-E20968FCDC6BQ41152619-456A5187-1692-4E00-87FA-499F469CA055Q41494834-1B36EBCB-00C4-48DB-A840-93454E6D2EF1Q43113878-8EE1A366-9F26-4D0C-A33F-3819C99826B0Q43901204-289E3342-983B-4E7F-99D1-ED73EABB3E43Q44224234-466C1A4A-8106-4AFD-81BA-1C310BCE2AE2Q44773696-46B90955-D464-4C6E-948F-9D8026FADBE4
P2860
Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Analysis of individual drug us ...... pulation-based cohort studies.
@ast
Analysis of individual drug us ...... pulation-based cohort studies.
@en
type
label
Analysis of individual drug us ...... pulation-based cohort studies.
@ast
Analysis of individual drug us ...... pulation-based cohort studies.
@en
prefLabel
Analysis of individual drug us ...... pulation-based cohort studies.
@ast
Analysis of individual drug us ...... pulation-based cohort studies.
@en
P2860
P1476
Analysis of individual drug us ...... pulation-based cohort studies.
@en
P2093
B H Ch Stricker
P2860
P2888
P304
P356
10.1007/S10654-010-9451-7
P577
2010-04-01T00:00:00Z
P5875
P6179
1020952633